mTOR inhibitors and autosomal dominant polycystic kidney disease.
Andrew S
AS
Levey
Lesley A
LA
Stevens
D018450:Disease Progression; D000068338:Everolimus; D005919:Glomerular Filtration Rate; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000473:pathology*; D009929:Organ Size / Q000187:drug effects; D016891:Polycystic Kidney, Autosomal Dominant / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors*
D000068338:Everolimus; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus